<![CDATA[Personalizing Treatment Selection in Platinum-Resistant Ovarian Cancer]]>

Summary

Ursula A. Matulonis, MD, discussed how biomarkers, adverse effects, and patient preference guide treatment choices among recently approved therapies for platinum-resistant ovarian cancer. The article is an expert commentary and does not report new data or specific regulatory events.